Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aspirin Use In Heart Patients Increases But Still "Suboptimum" - Study

This article was originally published in The Tan Sheet

Executive Summary

Aspirin usage in outpatients with coronary artery disease without contraindications increased from 5% in 1980 to 26.2% in 1996 in a representative sample of U.S. doctors' office visits, according to a study in the March 14 issue of the American Heart Association journal Circulation.

You may also be interested in...

Bayer Aspirin Ads Revised Under $1 Mil. FTC Settlement

Bayer ads cautioning aspirin therapy "is not appropriate for everyone" and offering a free consumer education brochure will break in February magazines under a $1 mil. settlement reached with the Federal Trade Commission.


Print ad in the June 17 New England Journal of Medicine for enteric-coated Bayer aspirin states, "Aspirin should be at the core of prevention. So why aren't more patients on aspirin?" Despite evidence that "aspirin-based therapy reduces vascular events among a broad range of at-risk patients...recent clinical studies and expanded FDA indications, millions of patients for whom aspirin may be appropriate still don't take it as part of their prevention regimen," the ad notes. "No other prevention medication is as affordable as aspirin," the ad concludes

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts